Le Lézard
Classified in: Health
Subjects: TDS, FVT

NuVasive To Present At The 36th Annual J.P. Morgan Healthcare Conference



SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, Jan. 8, 2018, at 1:30 p.m. PT / 4:30 p.m. ET.

NuVasive Logo

A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.


These press releases may also interest you

at 12:30
Today, the Lupus Foundation of America recognizes two leading scientists for their remarkable contributions to lupus research at the 2018 Evelyn V. Hess Reception to be held this evening in Chicago, Ill. during the 2018 American College of...

at 11:30
FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world's first 85cm wide bore computed tomography (CT)...

at 10:00
During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian shared details of its development work on an artificial intelligence (AI)-driven multimodality adaptive radiotherapy treatment suite that is...

at 09:30
Varian today announced the Bravostm afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by...

at 09:00
DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that data from systemic lupus erythematosus (SLE) and multiple sclerosis (MS) studies will be...

at 09:00
Royal Philips , a global leader in health technology, is showcasing its new suite of radiation oncology systems and software at the American Society for Radiation Oncology's (ASTRO) 60th Annual Meeting and Exhibition in San Antonio, Texas. Seamlessly...




News published on 3 january 2018 at 16:02 and distributed by: